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Purpose
To evaluate the disease course of patients with Juvenile
Idiopathic Arthritis (JIA) after discontinuation of etaner-
cept (ETA) and to determine prognostic factors of clinical
remission off medication.
Methods
Among patients with JIA treated with ETA from 2000 (n =
46), we identified patients in remission defined by a sus-
tained good clinical response according to physicians of
our departments for at least 1,5 years and discontinued
ETA. The disease course was evaluated using physician
and parent/patients VAS for disease activity, active joints,
joints with LOM, CHAQ, ESR, CRP. A bivariate analysis
of the relationship between JIA subtype, sex, age at onset
JIA, disease duration at start of ETA, MTX association,
time on ETA (before tapering and total), clinical remission
on ETA (defined by Wallace) and disease course was
undertaken using the Chi-square or Fisher’s exact test and
the Wilcoxon test.
Results
Among the 25 patients in clinical remission on medica-
tion, 16 have discontinued ETA at the moment of the ana-
lysis. Main characteristics were: 12 (75 %) female, mean
age at onset JIA was 5,5 years (1,4-13,2), JIA subtype were
oligoarthritis 7 (44%), polyarthritis 1 (6%), systemic arthri-
tis 5 (31%), enthesitis related arthritis 2 (12,5%), mean dis-
ease duration at start of ETA was 3,3 years (0,2-13), MTX
was associated to ETA in 11 (69%) cases, median total
time on ETA was 2,15 years (1,7-3,2). Discontinuation of
ETA was progressive for all patients except 3. After dis-
continuation, 13 patients are in clinical remission with a
median period of 1,8 years (0,5-2,2). Follow-up mean per-
iod (after ETA withdrawal) for these patients was 2,45
years (0,5-5,4). Only 3 patients experience flare with a
good response after reintroduction of ETA. Median time
to flare was 1,7 years (0,4-1,8). The bivariate analysis
didn’t reveal baseline values able to predict successful dis-
continuation of ETA without flare.
Conclusion
Our retrospective study confirms the possibility of ETA
discontinuation in JIA in case of long term of remission.
We did not identify predictive factors probably because
of the small cohort and, moreover, low number of
patients experiencing flare.
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